ArticleBiomarker research2026
Immuno-PET imaging of mesothelin in ovarian cancer with
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06843629 (Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMesothelin is highly expressed in ovarian cancer and represents a promising target for precision imaging and therapy. This study aimed to develop and evaluate ⁶⁸Ga-XH04, a novel mesothelin-targeted immuno-PET tracer for non-invasive imaging of mesothelin expression in preclinical models and patients.
methodsXH04, a high-affinity anti-mesothelin antigen-binding fragment (Fab), was engineered and conjugated with NOTA for radiolabeling with ⁶⁸Ga. Binding affinity and specificity were assessed in vitro using cell lines with graded mesothelin expression. In vivo PET imaging, biodistribution, and pharmacokinetics were evaluated in xenograft models. Immunohistochemistry was performed to correlate tracer uptake with mesothelin levels. A first-in-human pilot study was conducted in a healthy volunteer and ovarian cancer patients to assess safety, imaging characteristics, and descriptive comparison with ¹⁸F-FDG PET/CT.
results⁶⁸Ga-XH04 exhibited high radiochemical purity (> 98%) and nanomolar affinity for mesothelin. In preclinical models, ⁶⁸Ga-XH04 showed rapid clearance and higher uptake in mesothelin-high xenografts than in mesothelin-low xenografts, supporting exploratory assessment of mesothelin-dependent tracer accumulation. Immunohistochemistry confirmed the correlation between tracer uptake and mesothelin expression. In patients, ⁶⁸Ga-XH04 was well tolerated and visualized primary and metastatic lesions. In this preliminary cohort, ⁶⁸Ga-XH04 provided information complementary to ¹⁸F-FDG PET/CT and identified lesions with relatively low FDG uptake.
conclusion⁶⁸Ga-XH04 demonstrated the feasibility of specific, noninvasive, and high-contrast imaging of mesothelin expression in ovarian cancer with favorable pharmacokinetics. This tracer may complement existing imaging modalities by enabling noninvasive assessment of mesothelin expression and may provide imaging-based information to support future investigation of mesothelin-targeted therapies. Larger prospective studies are required to validate its diagnostic value and clinical utility.
trial registrationClinicalTrials.gov (NCT06843629); registered on December 20, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.